Key result
Intravenous dexmedetomidine administration during off-pump coronary artery bypass grafting significantly stabilized hemodynamics and reduced pro-inflammatory factors (IL-6, TNF-α, and CRP) compared to placebo.
Why the study?
To determine the effect of dexmedetomidine on hemodynamic changes and inflammatory responses in patients undergoing off-pump coronary artery bypass grafting.
Does intraoperative intravenous dexmedetomidine improve hemodynamic stability and reduce inflammatory responses in patients undergoing off-pump coronary artery bypass grafting?
RCT (n=239)
Double-blind
Sealed envelopes with serial numbers
No
Does intraoperative intravenous dexmedetomidine improve hemodynamic stability and reduce inflammatory responses in patients undergoing off-pump coronary artery bypass grafting?
Intraoperative dexmedetomidine infusion during off-pump coronary artery bypass grafting stabilizes hemodynamics and reduces the acute pro-inflammatory response.
Answers are grounded in this paper and cite their sources.
May support dexmedetomidine for hemodynamic stability in OPCABG; leaves open confirmation in larger outcome trials.
The aim of the present study was to determine the effect of dexmedetomidine on hemodynamic changes and inflammatory responses in patients undergoing off‑pump coronary artery bypass grafting (OPCABG). A total of 300 patients about to receive OPCABG were randomized evenly into the control group (n=116) and study group (n=123). Intravenous dexmedetomidine pump infusion was administered to patients in the study group at a rate of 0.4 µg.kg‑1.h‑1. The control group received physiological saline at the same infusion speed. Changes in hemodynamic parameters and inflammatory indices were compared between the two groups. Hemodynamic parameters, such as the heart rate and mean arterial pressure, were lower in patients from the study group, compared with that in the control group (both P<0.05). The levels of pro‑inflammatory factors, such as interleukin (IL)‑6, tumor necrosis factor‑α and C‑reactive protein, were also reduced in the study group (P<0.05). The observed levels of IL‑10 were lower in the control group compared with that in the study group, although a statistically significant difference was not achieved. Thus, the administration of dexmedetomidine in patients undergoing OPCABG stabilized hemodynamics and reduced inflammation. The present study was registered at the Chinese Clinical Trial Registry, under the trial registration number ChiCTR‑OOC‑15005978 (2015).
No takes yet. Share an insight, caveat, or question.
Zhai et al. (2020) conducted an RCT in Coronary artery disease requiring off-pump coronary artery bypass grafting (OPCABG) (n=239). Dexmedetomidine vs. Physiological saline was evaluated on Hemodynamic parameters (heart rate and mean arterial pressure) and inflammatory indices (IL-6, TNF-α, CRP) (p=<0.05). Intravenous dexmedetomidine administration during off-pump coronary artery bypass grafting significantly stabilized hemodynamics and reduced pro-inflammatory factors (IL-6, TNF-α, and CRP) compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: